Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine

Executive Summary

FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.


Related Content

Switches, Pediatric Products Highlight OTC Outlook In Independent Pharmacies
Independent Pharmacies Stock Growth Opportunities In Health, Wellness And Beauty Aisles
Returns From Sanofi Consumer Expansion Could Point To More
OTC Allergy Drugs: Not Just For Sniffles And Headaches, Sanofi Advises
Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
FDA's NDA And BLA Approvals: Tepadina, ArmonAir, Corphedra, Vyvanse, Xyzal Allergy
Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
Pharma Firm ISO OTC Switch Partner; NDA Experience, Resources Needed
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts